Skip menus, go to main page content

To Our Shareholders
and Investors

Top
To Our Shareholders and Investors

IR News

March 18, 2026

Pharmaceuticals

Launch of ELZONRIS® I.V. Injection for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Japan
March 18, 2026

Pharmaceuticals

Nippon Shinyaku start co-promotion activities of OPSUMIT® Pediatric Dispersible Tablets 1mg and 2.5mg for the Treatment of Pulmonary Arterial Hypertension
March 11, 2026

R & D

CAP-1002：Capricor Therapeutics Announces Establishment of New PDUFA Date
February 24, 2026

Pharmaceuticals

Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL

Upcoming Events

March 02, 2026
R&D Meeting
February 09, 2026
IR Meeting (Q3/FY2025)
February 09, 2026
FY2025 3rd Qtr Results Announcement
November 14, 2025
IR Meeting(Q2/FY2025)
November 14, 2025
FY2025 2nd Qtr results announcement

Financial/Capital Strategy

Management Policy and Plan

Business/Financial Information

IR Library

Sustainability Management

Stock and Shareholder Information

To Our Individual Investors

IR e-mail

Subscribe (only 1 minute required) to receive the latest news by e-mail.

Most Viewed Pages

March 1-31, 2026

All Japanese Listed Companies' Website Ranking

Gomez
IR Site Ranking Silver 2025

Daiwa Investor Relations Co.Ltd. 2025 Internet IR Award

Related Link

Nippon Shinyaku’s DNA

Research & Development

Top
To Our Shareholders and Investors